Introduction
Survivin is a member of the inhibitors of apoptosis (IAP) family of highly conserved proteins implicated in regulation of mitosis, cytokinesis, cell cycle and apoptosis (Altieri, 2003a; Altieri, 2003b; Fukuda & Pelus, 2006) . It is expressed during development but down regulated in most adult tissues. However, Survivin is over-expressed in the majority of solid tumors and leukemias, and is usually associated with higher proliferative index, reduced apoptosis, resistance to chemotherapy and increased rate of tumor recurrence, making it an attractive therapeutic target. We have previously shown that Survivin is expressed and growth factor regulated in normal hematopoietic cells and regulates apoptosis and cell cycle entry Fukuda et al., 2004; Fukuda & Pelus, 2001; Fukuda & Pelus, 2002) . Antagonizing Survivin impairs mouse progenitor cell production in vitro Fukuda et al., 2004) and loss of function upon conditional deletion in vivo leads to bone marrow ablation as a consequence of loss of stem cell function (Leung et al., 2007) . While Survivin is tightly regulated in normal hematopoietic cells, deregulated expression is frequently observed in hematologic diseases particularly those characterized by stem cell expansion. Survivin is aberrantly over expressed in acute myeloid leukemia (Adida et al., 2000; Carter et al., 2001 ) but down regulated in aplastic anemia where hematopoietic stem and progenitor cells are reduced (Badran et al., 2003) . It is now clear that Survivin can regulate cell growth under both physiological and pathological conditions. Therefore, identification of differential signaling cascades between normal and abnormal cells downstream of Survivin is required in order to identify cancer cell specific targets without toxicity to normal cells.
Survivin mediates aberrant proliferation of hematopoietic progenitor cells transformed by ITD-Flt3 188
2009; Gilliland & Griffin, 2002; Levis et al., 2005) . We reported that the combination of Flt3 ligand (FL), stem cell factor (SCF) and thrombopoietin (TPO) induces Survivin expression in human CD34+ cells (Fukuda & Pelus, 2001) , suggesting that Survivin lies downstream of Flt3 signaling. We therefore evaluated the effects of constitutive ITD-Flt3 signaling on Survivin expression. Survivin is up regulated by ITD-Flt3 in whole cells, as well as cells in G 0 /G 1 phase of the cell cycle (Figure 1 ) as determined by intracellular flow cytometric analyses. This suggests that up regulation of Survivin is not a consequence of cell cycle progression. Similarly, Survivin mRNA was up regulated in Ba/F3 cells by ITD-Flt3 compared to wild-type Flt3 following IL3 withdrawal. Up regulation of Survivin by ITD-Flt3 was associated with growth factor independent proliferation of Ba/F3 cells (Fukuda et al., 2009) . We next evaluated whether Survivin plays a role in aberrant growth factor-independent primary HPC proliferation upon transformation by ITD-Flt3. Over expression of human wild-type Flt3 in CFU-GM from control Survivin fx/fx or Survivin fx/fx mice harboring a tamoxifen-inducible Cre recombinase (Cre-ER TM ) failed to proliferate in vitro, whereas ectopic expression of ITD-Flt3 resulted in significant growth of CFU-GM in the absence of added growth factors. Treatment with 4OH-Tamoxifen to delete Survivin resulted in a significant reduction in the growth factor-independent proliferation of CFU-GM induced by ITD-Flt3 (Figure 2 ). Identical results were observed in the immunophenotypically defined c-kit + , Sca-1 + , Lineage negative (KSL) population of cells enriched for mouse stem and progenitor cells. These findings suggest that Survivin is involved in the growth factor-independent proliferation of HPC induced by ITD-F l t 3 an d t h at a n ta go n i z ing S u r v i v in ma y be therapeutically beneficial for acute myeloid leukemia (AML) expressing ITD-Flt3. 
Survivin regulated genes
While it is clear that antagonizing Survivin may reduce the aberrant proliferation of hematopoietic progenitor cells transformed by ITD-Flt3 and that ITD-Flt3 mutations are present in human leukemic stem cells (LSC) (Levis et al., 2005) , studies from our group and others indicate that Survivin is a normal regulator of hematopoietic stem and progenitor cells (HSPC) Fukuda et al., 2004; Leung et al., 2007 (Altieri, 2003a; Altieri, 2003b; Fukuda & Pelus, 2006) , we did not observe significant changes in genes that mediate apoptosis, suggesting that Survivin can regulate ITD-Flt3 transformed KSL cell fate independent of its ability to inhibit caspase activity. However, microarray analysis was performed on lineage marker negative viable cells that express GFP and stem cell markers and survived in culture, perhaps explaining lack of effects on genes involved in apoptotic pathways. The finding that Survivin deletion affected transcription was surprising since there is no direct evidence that Survivin regulates gene transcription. However, this is consistent with the fact that the Caenorhabditis elegans Bir1 Survivin homologue regulates transcription, most likely through effects on histone phosphorylation by Aurora kinase (Kostrouchova et al., 2003) . Survivin is essential for activation of Aurora kinase that phosphorylates histone H3 (Bolton et al., 2002; Chen et al., 2003) , an event required for transcriptional regulation (Cheung et al., 2000; Li et al., 2002; Nowak & Corces, 2000) and cytokinesis (Wei et al., 1999) . Furthermore, modulation of Survivin affects transcription in cancer cells (Asanuma et al., 2004; Balkhi et al., 2008; Takizawa et al., 2007) and transgenic Survivin expression alters gene expression in bladder cells (Salz et al., 2005) . Overexpression of Survivin also leads to phosphorylation of the Sp1 transcription factor (Asanuma et al., 2004) .
Survivin modulates expression of genes deregulated in human AML LSC
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Survivin modulates gene expression in LSC that connects through an EGFR signaling pathway
Functional annotation analysis indicates that genes related with dorso-ventral axis formation or epidermal growth factor receptor signaling pathway (EGFR) are significantly enriched in the shared genes associated with LSC and Survivin signaling in the KEGG database (http://www.genome.jp/kegg/) (P<0.03). Similarly, genes associated with regulation of EGFR signaling pathway are enriched in the Gene Ontology database (P<0.02). Our analysis shows that molecules shared by LSC and Survivin signaling are mapped on a functional signaling network that connects through the EGFR pathway (Figure 4) . EGFR signaling Fig. 4 . Genes regulated by Survivin in ITD-Flt3+ KSL cells and deregulated in LSC are mapped on a functional signaling network associated with the epidermal growth factor receptor signaling pathway. Epidermal growth factor receptor signaling pathway (EGFR) is significantly enriched in the shared genes associated with LSC and Survivin signaling by pathway enrichment analysis in KEGG and Gene Ontology databases. Our analysis shows that 13 molecules shared by LSC and Survivin signaling are mapped on a functional signaling network associated with EGFR. The network was created based on the KEGG database using Cytoscape software. Gray and black circle represents down regulation and up regulation by Survivin gene deletion, respectively. The hatched circle shows EGFR.
www.intechopen.com activates signaling cascades involved in cell proliferation, such as Src, Sos and MAP-kinases and is known to be dysregulated in a number of solid tumors (Alvarez et al., 2010; Harris & McCormick, 2010) . These findings suggest a potential role of EGFR signaling downstream of Survivin in AML stem cells, despite the fact that EGFR is not usually up regulated in AML cells (Hahn et al., 2009) . However, recent studies indicate an anti-neoplastic effect of an EGFR inhibitor in AML via off-target effects (Boehrer et al., 2008; Hahn et al., 2009 ). Thus, our data would support EGFR signaling as a candidate pathway for treatment of patients with AML, even though the number of molecules detected that associates with EGFR signaling is small.
Survivin splice variants
Survivin, like many genes, is alternatively spliced and variants having both similar or opposite activities have been identified, some of which are of prognostic significance (Fukuda & Pelus, 2006; Sampath & Pelus, 2007) . Spliced variants identified to date include Survivin 2 (Caldas et al., 2005; Mahotka et al., 2002) , 2B, Ex3 (Ling et al., 2005; Mahotka et al., 1999; Mahotka et al., 2002; Song & Wu, 2005) and 3B (Badran et al., 2004) , and some of these variants have been evaluated for their anti-or pro-apoptotic function and ability to interact with wild-type Survivin and other chromosomal passenger proteins (CPC) in some model systems. More recently, several new Survivin splice variants were found in the expressed sequence tag (est) database or described based on RT-PCR using RNA from Molt-4 cells (Li & Ling, 2006; Mola et al., 2007) , however the biological functions of these new variants are not known. Overall, with most all the variants reported to date, there is still a considerable lack of understanding of their biology and their function and prognostic value is only now being realized (Sampath & Pelus, 2007) . In order to better understand the biology of human Survivin splice variants, we cloned each variant and evaluated their antiapoptotic functions. In the process, we identified a new splice variant we termed Survivin 3 that is similar to Survivin 3B ( Figure 5 ). To determine if this was truly a novel variant, a forward primer specific for all splice variants and a splice variant specific reverse primer were designed and used to amplify cDNA using a polydT reverse transcribed cDNA library from HL60, K562 and Mo7e-Bcr-abl cells, the products resolved on an agarose gel and ~400bp bands excised, cloned and sequenced. Sequence analysis confirmed the presence of the novel splice variant. Survivin 3 contains 12 new amino acids at the Cterminus compared to wild-type Survivin and differs from all of the previously reported Survivin splice variants. Secondary structure prediction using Jpred suggests that Survivin 3 is structurally similar to wild-type Survivin, with the new amino acids predicted to be capable of forming a C-terminal helix that could potentially form the coiled coil domain, even though the length of this helix would be smaller than wild-type Survivin.
Expression of Survivin 3γ
Survivin 3 expression in primary cancer tissues was determined by quantitative RT-PCR on primary breast and prostate tumor samples obtained in an array format. In contrast to most cancers where wild-type Survivin is the predominant transcript, Survivin 3 was expressed at higher levels in benign prostate tissue and at equivalent levels in breast cancer cells. In primary breast cancer samples a statistically significant increase in wild-type Survivin expression at stages 1, 2 and 3 compared to control normal breast tissue was observed, with no significant difference observed between wild-type Survivin expression at stage 1 compared to later stages. In 7 normal breast tissue samples wild-type Survivin and Survivin 3 were expressed at the same level. However, in contrast to expression of wild-type Survivin, Survivin 3 expression remained relatively constant at all stages of disease, resulting in statistically significant (p<0.005) lower relative expression to wild-type Survivin. In 48 prostate cancers at different stages of the disease, wild-type Survivin expression was higher in stage 1 prostate cancer compared to benign hyperplasia; however sample size was too small to evaluate statistical significance. No clear over-expression of wild-type Survivin was seen at higher stages, except for a single stage 4 sample. The expression of Survivin 3 was higher than wild-type Survivin in benign hyperplasia tissue and comparison of the relative expression of wild-type Survivin and Survivin 3 at each stage of prostate cancer indicated that Survivin 3 transcripts remained higher than wild-type Survivin at all stages except stage 1. To our knowledge, the higher expression of Survivin 3 in benign prostate hyperplasia is the first demonstration of a Survivin splice variant expressed at higher levels than wild-type Survivin and suggest that it may play a role in normal cell function. The finding that Survivin 3 expression was higher than wild-type Survivin in benign prostate hyperplasia (BPH) samples and did not change with stage of disease is consistent with one study (Kaur et al., 2004) where Survivin expression was detected by immunohistochemistry. However, other reports show increased Survivin with stage of disease either at the RNA level by standard RT-PCR and gel electrophoresis (Kishi et al., 2004; Krajewska et al., 2003) or by immunohistochemistry (Krajewska et al., 2003) . The difference between our study and those reported using standard RT-PCR could be due to differences in sensitivity of the method used. SYBR green quantitative RT-PCR is more sensitive and efficient in amplifying smaller amplicons than conventional RT-PCR. We also show that expression of wild-type Survivin and Survivin 3 were comparable in normal breast tissues and that the expression of Survivin increased at stage 1 and remained high at all stages, whereas a recent report (Sohn et al., 2006) showed Survivin expression increased gradually at all disease stages. This difference could again be due to different methodologies and sensitivity between RNA analyses versus immunohistochemistry. Since the Survivin 3 splice variant was identified in the human HL-60 promyelocytic cell line, we evaluated its expression in other hematopoietic cells by quantitative RT-PCR using SYBR Green. While wild-type Survivin was the predominant transcript identified in all cell lines tested, Survivin 3 transcripts represented ~0.7-6% of the total Survivin transcripts detected. The absolute expression of Survivin 3 was lowest in growth factor dependant cells and highest in growth factor independent cells. Analysis of Survivin 3 in primary umbilical cord blood (UCB) CD34 + cells that are enriched for hematopoietic stem and progenitor cells showed that Survivin 3 was expressed at significantly higher levels than wild-type Survivin. This is in contrast to most splice variants that are expressed at lower levels than wild-type Survivin in these cells. However, growth factor stimulation induced a dramatic increase in expression of wild-type Survivin after 48 hours consistent with our previous findings Fukuda & Pelus, 2001; Fukuda & Pelus, 2002) , whereas the expression of Survivin 3 increased only slightly, therefore relative levels compared to wild-type Survivin decreased by ~2-fold. This suggests perhaps that Survivin 3 may play a role in hematopoietic stem cell maintenance.
Survivin 3γdemonstrates antiapoptotic activity
To evaluate the function of the novel Survivin 3 splice variants, we stably expressed human (Hu) wild-type Survivin with or without an N-terminal Flag-tag or Survivin 3 with an Nterminal HA-tag in murine YAC-1 lymphoma cells. Wild-type HuSurvivin, wild-type FlagHuSurvivin and HA-Survivin 3 were all expressed, although their levels of expression varied, with wild-type HuSurvivin expressing at 31-fold, whereas wild-type FlagHuSurvivin and HA-Survivin 3 were expressed at 76-and 63-fold higher levels, respectively than the empty vector control cells at the RNA level. Western blot analysis using a rabbit anti-Survivin polyclonal antibody that recognizes both the human and the murine Survivin showed background levels of murine Survivin as well as the presence of each of the transduced Survivins, indicating that each of the splice variants was translated. Analysis of band intensity indicated that wild-type HuSurvivin was expressed at the highest level followed by wild-type Flag-HuSurvivin with HA-Survivin 3 expressed at a lower level. The same pattern of expression was observed with a mouse anti-Survivin monoclonal antibody that recognizes predominantly human Survivin. As a measure of anti-apoptotic function we evaluated resistance of YAC-1 cells transduced with wild-type Survivin, wild-type Flag-Survivin and HA-Survivin 3 to the chemotherapeutic drugs Etoposide and Taxol at their optimal therapeutic dose. Treatment of cells with Taxol showed that, as expected, over expression of either wild-type Survivin or wild-type Flag-Survivin provided 2.7-and 2.8-fold resistance to Taxol-induced cell death, respectively, compared to YAC-1 cells transduced with vector control (Figure 6 ). Ectopic expression of HA-Survivin 3 provided 2.6-fold resistance. In multiple experiments, the IC 50's for wild-type HuSurvivin, wild-type Flag-HuSurvivin and HA-Survivin 3 were significantly higher than control (2.85 ± 0.32; P<0.05). YAC-1 cells expressing wild-type Survivin also showed significant resistance to Etoposide. Wild-type Flag-Survivin and HASurvivin 3 conferred resistance to Etoposide in YAC-1 cells to a similar degree as wild-type Survivin. These studies suggest that expression of Survivin 3 could potentially contribute to drug resistance. Expression levels of murine wild-type Survivin and the only known murine Survivin splice variant, Survivin-121 (Conway et al., 2000) were unchanged (not shown), indicating that changes in endogenous murine Survivin levels were not involved in the increase in resistance to chemotherapeutic compounds. These findings suggest that wildtype and Survivin 3 proteins possess equivalent anti-apoptotic function. Since crystal structure of wild-type Survivin indicates that the C-terminal helix could be involved in protein-protein interaction (Chantalat et al., 2000) and required for interaction with the chromosomal passenger protein, INCEP (Wheatley et al., 2004) , whereas the N-terminus of wild-type Survivin was unordered (Chantalat et al., 2000) , we hypothesized that addition of a C-terminal tag would hinder protein-protein interactions, therefore we engineered Nterminal tags into all the Survivin cDNAs. The presence of HA-tag at the N-terminus of the Survivin coding region did not affect activity since they were equivalent to N-terminal Flagtagged wild-type Survivin, which itself behaved similar to wild-type Survivin at least for drug sensitivity. The facts that Survivin 3confers drug resistance/anti-apoptotic function to two different classes of chemotherapeutic drugs Taxol, a microtubule destabilizing agent, and Etoposide, a topoisomerase II inhibitor, as well as growth factor independence similar to wild-type Survivin, and that it may be preferentially associated with maintenance of stem cell quiescence, makes it an interesting potential therapeutic target . 
Summary
We have shown that ITD-Flt3 mutations increase expression of Survivin, which regulates development of ITD-Flt3 + acute leukemia, clearly indicating a potential therapeutic benefit for antagonizing Survivin in patients with ITD-Flt3 + AML (Fukuda et al., 2009; Fukuda et al., 2011; Sampath & Pelus, 2007) . However, we have shown that Survivin also regulates normal HSPC function (Fukuda et al., 2004; Fukuda & Pelus, 2002; Leung et al., 2007; Sampath & Pelus, 2007) ; raising caution that targeting Survivin can have hematopoietic toxicity. Therefore, identification of differential signaling cascades downstream of Survivin between normal hematopoietic cells versus cancer and leukemia stem cells is required to pinpoint targets that can lead to effective anti-malignant therapies with acceptable normal stem cell toxicity. Our genetic profiling using normal and ITD-Flt3 transformed cells from conditional Survivin knockout mice has identified a panel of genes that are specifically regulated by Survivin in ITD-Flt3 transformed cells and known to be deregulated in human LSC that can be potentially targeted for selective anti-leukemia therapy. Inherited and acquired changes in pre-mRNA splicing have been documented to play a significant role in human disease development and loss of fidelity or variation of the splicing process may play a major role in carcinogenesis (Fackenthal & Godley, 2008; Matlin et al., 2005; Skotheim & Nees, 2007) . Splice variants that are found predominantly in tumors have clear diagnostic value (Brinkman, 2004; Caballero et al., 2001 ) and may provide potential drug targets. Splice variants of Survivin have been reported but their prognostic value is not clear, partially based upon detection methods that are not sufficiently specific (Sampath & Pelus, 2007) , or due to lack of information on biological function. We have identified a novel Survivin splice variant with anti-apoptotic activity similar to wild-type Survivin, at least with respect to sensitivity to chemotherapeutic drugs. We characterized its expression in several transformed cell lines, and similar to other Survivin splice variants, wild-type Survivin is the predominant transcript. However, in contrast to wild-type Survivin, Survivin 3 expression does not change with increasing stage/severity of primary prostate and breast cancers. In addition, unlike other Survivin splice variants, Survivin 3 is expressed at higher levels than wild-type Survivin in primary HSPC, and their lack of increase with cell proliferation suggests that they may play a role in stem cell maintenance. Since Survivin 3 was cloned from and found to be highly expressed in hematopoietic cells, it will be particularly interesting to evaluate its expression in hematopoietic malignancies and their correlation with disease/stage/survival. Furthermore, since ITD-Flt3 mutations increase Survivin expression, it will be interesting to determine if they also modulate Survivin 3 expression and how this relates to disease progression and prognostic value. Given the specific genes regulated by Survivin in leukemic stem cells, it will also be of interest whether Survivin 3 elicits overlapping or divergent gene products that can be utilized for development of anti-leukemia therapies. Adida, C. et.al (2000) . Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol, Vol.111:196-203. Altieri, D.C. (2003a) . Survivin, versatile modulation of cell division and apoptosis in cancer.
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